Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP2 | O95551 | 2/20 | 0.47 |
| ▸ | KIF11 | P52732 | 11/20 | 0.44 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.40 |
| ▸ | ESR1 | P03372 | 1/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.39 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.37 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.37 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.36 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | BRAF | P15056 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4889102 | 1.00 | TDP2 (0.47) | TDP2KIF11ASIC3ESR1ESR2 | |
| SCHEMBL30996923 | 0.77 | HSD17B1 (0.42) | TDP2KIF11ASIC3ESR1ESR2 | |
| SCHEMBL4893296 | 0.76 | TDP2 (0.57) | TDP2KIF11ASIC3CHRNB2CHRNA4 | |
| SCHEMBL1479810 | 0.75 | TDP2 (0.68) | TDP2KIF11ASIC3ESR1ESR2 | |
| SCHEMBL5378351 | 0.74 | NPC1 (0.33) | CA1CA2 | |
| SCHEMBL5378345 | 0.74 | NPC1 (0.33) | CA1CA2 | |
| SCHEMBL29187397 | 0.72 | HSD17B1 (0.44) | TDP2KIF11ASIC3ESR1ESR2 | |
| SCHEMBL30996924 | 0.72 | HSD17B1 (0.44) | TDP2KIF11ESR1ESR2BRAF | |
| SCHEMBL8883867 | 0.70 | ASIC3 (0.42) | TDP2ASIC3 | |
| SCHEMBL4151074 | 0.70 | ASIC3 (0.42) | TDP2ASIC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080176830-A1 | Compounds, Compositions, and Methods | ADAMS NICHOLAS D | 2008-07-24 | — | — | US | claimed |
| US-20080176830-A1 | Compounds, Compositions, and Methods | ADAMS NICHOLAS D | 2008-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176830-A1 | Compounds, Compositions, and Methods | ALPP, PCNA, MKI67 | TDP2 1033/4885KIF11 562/4885ASIC3 4725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.